A panel of experts on nasopharyngeal carcinoma review patient cases and provide comprehensive insights on treatment practices.
EP. 1: Differentiating Nasopharyngeal Carcinoma from Other Head & Neck Cancers: The Value of a Multidisciplinary Approach
Experts on nasopharyngeal carcinoma (NPC) provide an overview of the disease, highlighting its incidence, how it’s differentiated from other head and neck cancers, and the benefits of multidisciplinary care.
EP. 2: Current Guidelines for Managing Nasopharyngeal Carcinoma
Shravan Kandula, MD, reviews the current guidelines for the treatment of patients with nasopharyngeal carcinoma.
EP. 3: Overview of the JUPITER and POLARIS-2 Trials
Victoria M. Villaflor, MD, provides insights on the role of immune checkpoint inhibitors in treating nasopharyngeal carcinoma, focusing on the JUPITER and POLARIS-2 clinical trials.
EP. 4: Value of PD-L1 Biomarker in NPC
A medical oncologist discusses the value of PD-L1 as a biomarker in the treatment of patients with nasopharyngeal carcinoma.
EP. 5: Phase 3 DIPPER Trial: Adjuvant PD-1 Blockade with Camrelizumab
Shravan Kandula, MD, reviews findings from the DIPPER trial, which is investigating adjuvant PD-1 blockade with camrelizumab in patients with nasopharyngeal carcinoma.
EP. 6: Tailoring NPC Treatment: Patient Populations, EBV Titer Monitoring, and Key External Factors
Experts on nasopharyngeal carcinoma outline the role of immunotherapy and discuss external factors that inform treatment decisions.
EP. 7: Strategies to Mitigate Adverse Events in Nasopharyngeal Carcinoma Treatment
Victoria M. Villaflor, MD, highlights ways to mitigate adverse events for patients receiving treatment for nasopharyngeal carcinoma.
EP. 8: Future Research Needs for Neoadjuvant/Adjuvant PD-1 Blockade in Nasopharyngeal Carcinoma
The panel provides clinical insights on nasopharyngeal carcinoma treatment practices and outlines unmet needs in the current therapeutic landscape.
EP. 9: Integrating PD-1 Inhibitors into Standard NPC Treatment: Potential Benefits and Future Prospects
Victoria M. Villaflor, MD, discusses the integration of PD-1 inhibitors into standard treatment practices for patients with nasopharyngeal carcinoma.
EP. 10: Clinical Scenario: Locally Recurrent NPC
Shravan Kandula, MD, presents the case of a patient with locally recurrent nasopharyngeal carcinoma.
EP. 11: Clinical Scenario: Metastatic EBV-Positive NPC
The panel provides clinical insights on the treatment of a patient with metastatic EBV-positive nasopharyngeal carcinoma.
DK210 (EGFR) Induces Immune Response Without Increased CRS or Regulatory T Cells in Solid Tumors
Siglec-15 Represents Potential Therapeutic Target in NSCLC, Other Solid Tumors
Radiomic Biomarkers Predict Response in Lung and Liver Uveal Melanoma Metastases
BT7480 Shows Preliminary Activity in Nectin-4+, CD137+ Tumors